Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 2/20 | 0.32 |
| ▸ | MAOB | P27338 | 2/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD1 | P21728 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | DRD5 | P21918 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14084282 | 0.80 | OPRM1 (0.33) | DRD3ALDH1A1HTT | |
| SCHEMBL28159652 | 0.76 | DRD3 (0.35) | DRD3 | |
| SCHEMBL17029518 | 0.76 | DRD3 (0.35) | DRD3 | |
| SCHEMBL13931717 | 0.76 | HRH3 (0.35) | DRD3HRH3MAOAMAOBDRD2 | |
| SCHEMBL10881206 | 0.76 | DRD3 (0.43) | DRD3 | |
| SCHEMBL14808997 | 0.76 | DRD3 (0.36) | DRD3 | |
| SCHEMBL30990313 | 0.76 | DRD3 (0.43) | DRD3HRH3SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL18975892 | 0.75 | — | — | |
| SCHEMBL28153950 | 0.71 | DRD3 (0.37) | DRD3 | |
| SCHEMBL31719552 | 0.71 | DRD3 (0.40) | DRD3HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2976339-A1 | GEMINALLY SUBSTITUTED CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-01-27 | — | — | EP | disclosed |
| WO-2014146249-A1 | GEMINALLY SUBSTITUTED CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014146491-A1 | GEMINALLY SUBSTITUTED CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-8629277-B2 | Styrenyl 1,2,4-oxadiazole compounds | Piramal Enterprises Limited (IN) | 2014-01-14 | — | — | US | disclosed |
| US-20130005771-A1 | OXADIAZOLE COMPOUNDS, THEIR PREPARATION AND USE | Piramal Enterprises Limited (IN) | 2013-01-03 | — | — | US | disclosed |
| US-8202871-B2 | Indol-2-one derivatives disubstituted in the 3-position, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2012-06-19 | — | — | US | disclosed |
| EP-2188253-B1 | Indol-2-one derivatives disubstituted in 3-position, preparation thereof and therapeutic use thereof | SANOFI SA (FR) | 2012-03-07 | — | — | EP | disclosed |
| US-20110118280-A1 | INDOL-2-ONE DERIVATIVES DISUBSTITUTED IN THE 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-05-19 | — | — | US | disclosed |
| US-20100210662-A1 | INDOL-2-ONE DERIVATIVES DISUBSTITUTED IN THE 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-08-19 | — | — | US | disclosed |
| EP-2188253-A2 | INDOL-2-ONE DERIVATIVES DISUBSTITUTED IN THE 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009056707-A2 | INDOL-2-ONE DERIVATIVES DISUBSTITUTED IN THE 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-05-07 | — | — | WO | disclosed |
| US-7160900-B2 | Tetrahydropyridino or piperidino heterocyclic derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210662-A1 | INDOL-2-ONE DERIVATIVES DISUBSTITUTED IN THE 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | IDO2, IDO1, TPH2 | DRD3 32/4885HRH3 911/4885MAOA 55/4885 |
| US-20110118280-A1 | INDOL-2-ONE DERIVATIVES DISUBSTITUTED IN THE 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | IDO2, IDO1, TPH2 | DRD3 32/4885HRH3 911/4885MAOA 55/4885 |
| US-20130005771-A1 | OXADIAZOLE COMPOUNDS, THEIR PREPARATION AND USE | MCL1, OXA1L, ABL1 | DRD3 1760/4885HRH3 1655/4885MAOA 739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.